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Background: The cytokine MIF (Macrophage Migration Inhibitory Factor) has diverse physiological roles and is
present at elevated concentrations in numerous disease states. However, its molecular heterogeneity has not been
previously investigated in biological samples. Mass Spectrometric Immunoassay (MSIA) may help elucidate MIF
post-translational modifications existing in vivo and provide additional clarity regarding its relationship to diverse
pathologies.
Results: In this work, we have developed and validated a fully quantitative MSIA assay for MIF, and used it in the
discovery and quantification of different proteoforms of MIF in serum samples, including cysteinylated and glycated
MIF. The MSIA assay had a linear range of 1.56-50 ng/mL, and exhibited good precision, linearity, and recovery
characteristics. The new assay was applied to a small cohort of human serum samples, and benchmarked against
an MIF ELISA assay.
Conclusions: The quantitative MIF MSIA assay provides a sensitive, precise and high throughput method to
delineate and quantify MIF proteoforms in biological samples.
Keywords: Proteomics, MALDI-TOF, Biomarker discovery, Immunoassay, Quantification, Post-translational
modifications, MIFBackground
MIF (Macrophage migration inhibitory factor) is a widely
expressed 12.3 kDa cytokine with diverse physiological
activities. It was first discovered in 1966 by Bloom and
Bennett [1] as a component of an exudate that demon-
strated the ability to inhibit random movement of macro-
phages in vitro. It was successfully cloned by Weiser et al.
[2], revealing the approximate molecular weight of MIF,
and facilitating preliminary investigations of its physio-
logical activities. More recently it has been determined
that MIF activities are mediated through extracellular re-
ceptor CD74 [3], with activation of the intracellular signal-
ing cascade facilitated by CD44 [4]. MIF also functionally* Correspondence: dobrin.nedelkov@asu.edu
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unless otherwise stated.binds with chemokine receptors CXCR2 and CXCR4
[5], and the intracellular protein Jab1 [6]. Unlike most
other cytokines, which are synthesized in a de novo
manner, MIF is expressed constitutively and stored
intracellularly [7].
In recent years our knowledge of MIF function has ex-
panded to encompass diverse physiologic functions, includ-
ing immune [7,8], neuroendocrine [9,10], and enzymatic
[11-13] activities. Of note, MIF possesses several catalytic
properties, including thiol protein oxidoreductase [12] and
tautomerase activities [11,13].
In vitro, murine, and clinical studies have indicated
that MIF is a key regulator of both adaptive and innate
immune functions, and also modulates the inflammatory
response [7,8]. MIF stimulates the release of other pro-
inflammatory molecules via an autocrine mechanisml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the inflammatory response [15]. In humans, increased
circulating concentrations of MIF have been reported in
inflammatory conditions such as sepsis [16,17] and
rheumatoid arthritis [18]. MIF has demonstrated poten-
tial to serve as a prognostic marker in critically ill sepsis
patients [19], and as a marker of pulmonary function fol-
lowing cardiopulmonary bypass [20].
A number of in vitro, in vivo, and clinical studies have
indicated a potential involvement of MIF in the develop-
ment of cardiovascular and metabolic disorders [21-28]. It
has been found that MIF might be involved in the early
stages of plaque development [22], and that it can pro-
mote destabilization of atherosclerotic plaques [26,28]. In
mouse models, it can promote intimal thickening [23,27]
and induce cardiac dysfunction [24], although one study
[29] found that MIF may exert cardioprotective effects in
the context of ischemic injury. Numerous clinical studies
have reported elevated circulating levels of MIF in the
context of cardiovascular and metabolic pathologies, in-
cluding acute myocardial infarction [21,30], chronic kid-
ney disease [31], and type 2 diabetes [32-34].
Studies of MIF function and expression in cancer have
revealed a largely pro-tumorogenic role. MIF inhibits the
action of tumor suppressor p53 [35], and has been im-
plicated in the development and progression of breast
[36] and lung cancer [37,38]. MIF has also been noted to
circulate at elevated levels in a number of cancer sub-
types, including ovarian [39], colorectal [40], breast [36],
and prostate cancer [41].
While immunoassays such as ELISA and RIA are com-
monly used for measuring circulating protein concentra-
tions, mass spectrometry-based approaches are becoming
increasingly relevant to the clinical setting for diagnostic
applications [42-44]. Recently, Campa et al. developed a
mass spectrometry-based platform for MIF and cyclophi-
lin A to quantify these proteins in non-small cell lung can-
cer (NSCLC) [45].
In recent years, proteomic and mass spectrometry
techniques have furthered the discovery and comprehen-
sion of protein post-translational modifications (PTMs),
which may have unique physiologic activities, and can
be associated with or be by products of disease processes
[46,47]. As such, PTMs may potentially serve as clinic-
ally useful markers for diagnosis, prognoses, or therapy
monitoring. Accordingly, it is imperative to develop ana-
lytical techniques that can not only quantify total protein
levels in biological samples, but also have the ability to
discriminate between different isoforms of the target
protein.
Several in vitro studies have demonstrated unique bio-
logical activities of MIF post-translational modifications. It
was recently discovered that MIF is the main target of
PEITC (phenethyl isothiocyanate) which binds intracellularMIF at the N-terminus, diminishing MIF tautomerase
enzyme activity [48]. Additionally Watarai et al. [49]
demonstrated in vitro cysteinylated MIF (described by
its synonym GIF) to possess elevated physiologic ac-
tivity and specific immunosuppressive activities not ob-
served for unmodified MIF, and determined the site of
this modification.
While in vitro investigations have provided valuable
insights into the activities of post translationally modi-
fied forms of MIF, studies of the heterogeneity of MIF in
biological samples have not been previously performed.
While total concentration of circulating MIF can be effi-
ciently analyzed by ELISA assays, distinct forms of MIF
cannot be differentiated. As such, a technique that can
provide qualitative and quantitative analyses of MIF
levels in biological matrices could facilitate the discovery
of previously undetected MIF proteoforms, and may fur-
ther our comprehension of the relationship of MIF with
diverse pathologies.
Mass Spectrometric Immunoassay (MSIA), an immu-
noenrichment technique that was developed by Nelson
et al. [50], utilizes antibodies immobilized to an acti-
vated solid support within an affinity pipette tip to cap-
ture the target protein species from a biological sample,
which is then followed by elution and mass spectrometric
analysis. Quantitative MSIA analyses can be performed
wherein an internal reference standard is introduced into
the biological sample and co-captured with the target pro-
tein in parallel to generate a standard curve. A number of
MSIA assays have been developed for either single or mul-
tiple target proteins, with the ability to provide simultan-
eous qualitative and quantitative analyses within a single
assay [51-53]. Here we describe the development, valid-
ation, and application of a qualitative and quantitative
MSIA assay for Macrophage Migration Inhibitory Factor
(MIF). The assay can both quantify and discern the mo-
lecular heterogeneity of this multifunctional cytokine.
Results
Assay development
Pooled human plasma from healthy donors was used for
the initial assay development. It was determined experi-
mentally that an addition of detergent buffer provided
optimal MIF signal-to-noise ratio, with minimal pres-
ence of non-specifically bound proteins in the mass
spectra. The detergent buffer had been developed for
prior MSIA analyses [54,55].
Important to the development of the quantitative assay
is the selection of an internal reference standard (IRS)
that can simultaneously be retrieved from the sample
along with the native protein and produces a consistent
signal in the mass spectrum that is distinct from any
naturally occurring isoforms of the target protein. We
selected C-terminally labeled His tag MIF which has a
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standard that is in the same m/z range as human MIF,
but adequately shifted from human MIF in a spectrum
region free of peaks, potential overlap with endogenous
forms of human MIF is averted.
Shown in Figure 1 is a representative mass spectrum
from the MIF MSIA performed on a serum sample to
which 10 ng/mL His tag MIF has been added as an in-
ternal reference standard (IRS). Peaks in the mass
spectrum correspond to endogenous forms of MIF, includ-
ing native (intact) MIF (m/zobs = 12346.1), cysteinylated
MIF (m/zobs = 12465.0, m/zcalc = 12465.3) and glycated
MIF (m/zobs = 12509.6, m/zcalc = 12508.3). Also present
are peaks of the sinapic acid matrix adduct (m/zobs =
12551.9, m/zcalc = 12552.2) and His tag MIF (m/zobs =
13411.1, m/zcalc = 13411.2).
Also important to assay development is the selection
of a suitable matrix in which to perform standard curve
dilutions. We considered animal plasma due to similarity
in properties to human plasma. However, this was not
feasible, due to the cross reactivity of the MIF antibody
with endogenous goat, bovine, and equine MIF. As such,
we utilized 10 mg/mL of Human Serum Albumin in
PBS, a solution roughly iso-tonic and iso-osmotic to hu-
man plasma/serum.
Assay validation
Recent years have brought about rapid advances in bioa-


















Figure 1 Representative MIF Spectra from MSIA performed on health
MIF, cysteinylated MIF, glycated MIF, sinapic acid matrix adduct, andresearch [47] and clinical use of mass spectrometers [42,43]
for quantitative analyses. As such, there is a growing inter-
est in streamlining pre-study validation measures to ensure
reliable assay performance [56-59]. The performance char-
acteristics that were evaluated for the MIF MSIA assay in-
cluded intra-assay (within run) and inter-assay (between
runs) precision, spiking recovery, and dilution linearity.
To analyze the intra-assay and inter-assay precision, a
3-day experiment was performed in which 3 replicates
of a single serum sample were analyzed per day by
MSIA. A standard curve was run with each analysis. A
representative standard curve, along with the MIF stan-
dards mass spectra, is shown in Figure 2. A linear dy-
namic range was observed with the standard curve, with
an average R-squared for all three days of 0.99. The
intra-day CV values were 3.97%, 8.42%, and 3.14% re-
spectively, and the inter-day CV was 8.21% (Table 1).
To analyze the dilution linearity of endogenous MIF,
two experiments involving serial two-fold dilutions were
performed with serum samples with a known intact MIF
concentration, on two separate days. The serum sample
was diluted 2×, 4×, and 8× in a 10 ng/mL solution of
HSA in PBS. The concentrations were calculated via the
accompanying standard curve. The percent recovery was
determined by dividing the observed by the expected
concentrations (Table 2).
To analyze the spiking recovery, two experiments were
performed, on two separate days, in which a serum sam-
ple containing a low endogenous concentration of MIF13000 13500 14000 m/z
d MIF
MIF
His tag MIFIF + Sinapic
cid – H2O
y male serum sample with peaks corresponding to native (intact)
His tag MIF.
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Figure 2 Representative standard curve for MIF MSIA with linear range of 1.56 - 50 ng/mL. a) MIF-to-His tag MIF ratios are plotted against
concentrations of standards to create the plot; b) Representative MALDI TOF mass spectra from the MIF and His tag MIF standards used to generate
the standard curve.
Table 1 Intra- and inter-assay precision
Intra-assay CVs Inter-assay CV
Day: 1 2 3
STDEVP: 1.23 3.01 1.18 STDEVP 2.85
MEAN (ng/mL): 30.9 35.7 37.7 MEAN 34.8
CV (%): 3.97 8.42 3.14 CV 8.21
3 replicates of a serum sample were analyzed per day on 3 consecutive days.
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ment, four 200 μL aliquots of the serum sample were
supplemented with 20, 10, 5, and 0 ng/mL of recombin-
ant MIF protein respectively, via addition of 100 μL of
40 ng/mL, 20 ng/mL, 10 ng/mL, and 0 ng/mL of recom-
binant MIF protein (prepared in PBS-HSA buffer). A
100 μL aliquot of IRS (40 ng/mL His tag MIF in PBS-
HSA buffer), and a 100 μL aliquot of detergent buffer
were then added to the samples and standards, and
MSIA was performed. The MIF concentrations were
Table 2 Assay linearity
Sample Dilution Observed Expected Recovery
ng/mL ng/mL O/E %
1 31.5
2× 15.5 15.7 98.3
4× 7.36 7.87 93.5
8× 4.20 3.93 107
2 29.2
2× 13.6 14.6 93.2
4× 7.00 7.30 95.9
8× 4.20 3.65 115
Serum samples were, on two separate days, serially diluted 2×, 4× and 8× and
MSIA was performed. Intact MIF concentrations were determined from
accompanying standard curve.
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tion. The percent recovery of MIF in each sample was
determined from the ratio of observed to expected con-
centrations (Table 3).
Method comparison - MSIA and ELISA analyses of MIF
concentrations in healthy serum samples
The optimized and validated MSIA MIF assay was used
to analyze serum samples obtained from 22 healthy
males ranging in age from 46 to 73. The serum samples
were analyzed by quantitative MSIA in parallel with an
accompanying standard curve, as described in the previ-
ous section. The standard curve exhibited good linearity,
with an R-squared value of 0.99. A peak corresponding
to glycated MIF was observed in 21 of the 22 samples,
and a peak corresponding to cysteinylated MIF was ob-
served in 18 of the 22 samples. The total MIF concentra-
tions (sum of all MIF isoform concentrations) ranged
from 11.9 to 92.7 ng/mL, with a mean of 36.2 ng/mL.
Cysteinylated MIF concentrations ranged from 1.82 to
5.44 ng/mL and glycated MIF concentrations ranged
from 1.82 to 17.40 ng/mL.Table 3 Spiking recovery
Sample MIF added Observed Expected Recovery
ng/mL ng/mL ng/mL O/E%
1 0 12.5
5 16.3 17.5 93.1
10 20.9 22.5 92.9
20 31.5 32.5 96.9
2 0 15.4
5 21.9 20.4 108
10 24.8 25.4 97.7
20 35.1 35.4 99.2
A serum sample was fortified with 0 ng/mL, 5 ng/mL, 10 ng/mL, and 20 ng/mL
recombinant MIF protein and MSIA was performed. Intact MIF concentrations
were determined from accompanying standard curve.ELISA for the 22 serum samples was performed with
Quantikine ELISA kit (R&D systems), but using Fitzgerald
MIF protein in place of R&D Systems MIF standard.
The samples were run in duplicate and the concentra-
tions were averaged. The assay was performed accord-
ing to the manufacturer instructions, on a Thermo
Scientific Multiskan GO spectrophotometer. The MIF
concentrations ranged from 11.7 to 91.7 ng/mL, with a
mean of 42.8 ng/mL.
A good correlation was observed between ELISA MIF
and MSIA total MIF concentrations, with a negative 17.7
percent bias, as revealed by the Altman-Bland [60,61]
plot (Figure 3), which shows (a) a Scatter plot and (b) a
Difference plot. A Passing Bablok [62] regression equation
of y = −2.76 + 0.89× was obtained, with a Cusum linearity
p value of 0.78.
Stability analyses of MIF protein standard
Changes in protein stability as a result of variations in
sample storage and handling may introduce unantici-
pated analytical variability [63]. As such, efforts must be
undertaken to experimentally identify potential sources
of variability that may affect the analysis, and to estab-
lish the optimal storage and handling conditions for the
samples and protein standards. Accordingly, we per-
formed experiments to assess the stability of the 1 mg/
mL recombinant MIF protein under the following condi-
tions: storage undiluted at −80°C, storage diluted in
40 ng/mL PBS-HSA buffer at −80°C, and prolonged stor-
age undiluted at 4°C.
To evaluate the stability of the 1 mg/mL Fitzgerald
MIF protein when it is stored at −80°C but thawed and
re-frozen after each use, we performed a three-day ex-
periment in which a tube of 1 mg/mL recombinant MIF
protein was stored at −80°C. On each of three days, the
tube was thawed and an aliquot was removed and used
to fortify a plasma sample with 20 ng/mL MIF. The tube
was then placed back at −80°C. Plasma from the same
individual was used on each day. Pre-aliquoted His tag
MIF was added fresh on each day into the spiked plasma
sample at 10 ng/mL prior to MSIA analysis. The ratio of
MIF/HisMIF peak intensities decreased on each subse-
quent day, from 24.56 to 20.45 to 13.71, an average day-
to-day decrease of 24.85%.
To determine whether the MIF protein is stable in
terms of its immunoreactivity toward anti-MIF antibody
when stored frozen in a solution of albumin in PBS buffer,
we performed an experiment in which 1 mg/mL recom-
binant MIF protein was diluted to 0.1 mg/mL in 40 ng/ml
PBS-HSA buffer and stored at −80°C. On each of 3 days,
the 10× diluted MIF protein was taken out and used to
fortify a plasma sample to 20 ng/mL. Pre-aliquoted His
tag MIF was added fresh on each day into the sample at
10 ng/mL immediately prior to MSIA analysis. The MIF/
ab
Figure 3 Histogram of MIF concentrations determined by MSIA and ELISA for 22 healthy male serum samples. a) Scatter plot showing
the direct comparison between the MIF concentrations obtained with developed MSIA and reference ELISA method; b) Altman-Bland difference
plot reveals slight negative correlation (bias = −17.7%) between the MIF concentrations obtained by MSIA vs the reference ELISA method.
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were relatively consistent from days one through three (an
average variation of 4.11% per day), indicating that the
MIF protein was stable when stored frozen at -80°C.
To analyze the stability of MIF protein when stored at
4°C, we performed an experiment in which recombinant
MIF protein from a freshly received vial at 1 mg/mL
concentration was stored at 4°C and used to fortify a
plasma sample with 20 ng/mL of MIF. The experiment
was repeated after 6 and 12 days. Pre-aliquoted His tag
MIF at 10 ng/mL was added fresh on each day just prior
to MSIA analysis. The MIF/HisMIF peak intensity ratios
were evaluated and remained relatively unchanged after
both 6-day and 12-day intervals. The ratios were 15.72,
15.10, and 15.61 on days 0, 6, and 12, an average vari-
ation of 3.66% per day. As such, we concluded that the
recombinant MIF protein is stable for at least 12 days
stored at 4°C, and employed this sample storage for the
analyses.
Quantitative comparison of MIF in different specimen
collection types
Anti-coagulants such as EDTA, heparin, and citrate are
often added to plasma collection tubes, inhibiting coagu-
lation via unique mechanisms [64]. However, differences
in plasma collection tube additives may produce sample
characteristics that result in differences in measurable
protein concentrations, and this may introduce analytical
bias into a quantitative biomarker investigation when
not accounted for [63]. Hence, it is important to deter-
mine how differences in sample collection tubes may
affect the analysis, and to determine the optimal speci-
men type for the analysis.
With this in mind, we performed a quantitative MIF
MSIA analysis in order to compare the differences in
measurable MIF concentrations among different sampleFigure 4 Comparison of total MIF concentrations among different sam
Friedman’s test with multiple pairwise comparisons, are indicated by p-valucollection types. We analyzed matched sets obtained
from Bioreclamation, of 5 samples each, from 6 donors
(30 samples total). Each set of 5 samples consisted of
one serum sample and four plasma samples: 3.8% NaCi-
trate plasma, K2EDTA plasma, K3EDTA plasma, and
Na2EDTA plasma.
Total MIF concentrations were higher in serum than
any of the plasma types, and lowest in Na2EDTA plasma
and 3.8% NaCitrate plasma. Box Plots of total MIF con-
centrations comparing different sample collection types
are shown in Figure 4. Friedman’s test with multiple
pairwise comparisons was carried out to look for signifi-
cant differences between sample types. Significant differ-
ences, indicated by p-values of <0.005, were found for
serum vs 3.8% NaCitrate plasma, for serum vs Na2EDTA
plasma, and between 3.8% NaCitrate plasma vs K2EDTA
plasma.
MIF glycation mapping
We observed a peak corresponding to a tentative MIF
glycation event in 21 of the 22 healthy male serum sam-
ples that we analysed by MSIA. To characterize this
modification and potentially pinpoint its molecular loca-
tion, we developed an in-solution pepsin digest method
and initially applied it to in vitro glycated recombinant
MIF, with the goal of applying the pepsin digestion pro-
cedure to a MSIA MIF elution of a serum sample that
contains endogenous glycated MIF. MIF has 3 lysines
(potential glycation sites) at positions 32, 66, and 77 -
Figure 5. In-solution pepsin digest was performed for
both unmodified and artificially glycated MIF as de-
scribed in the methods section. In-solution pepsin digest
resulted in 100% sequence coverage based on mass map-
ping. In the digest spectra of glycated recombinant MIF,
4 unique glycated fragments were identified on the basis
of mass mapping to within 0.1 Da mass accuracy, andple collection types. Significant differences, determined by
es of <0.005. Matching symbols designate significant differences.
Figure 5 Sequence of intact MIF, with lysine residues highlighted.
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a peptide corresponding to glycated I[4-46]L, a peptide
corresponding to C[59–82]L and peptides corresponding
to both single and double glycation of fragment C[59–83]
L which has lysines at 66 and 77. As such, it is likely that
recombinant, artificially glycated MIF can be glycated at
all three lysine residues. Additional studies will need to be
undertaken to determine if endogenous MIF is glycated in
a site-specific manner.
Discussion
The MSIA workflow enables an efficient and high-throughput
analysis of up to 96 samples in parallel, using an auto-
mated robotic workflow for both antibody coupling and
immunoaffinity enrichment of analytes. The ability to
identify non-specifically bound proteins, as well as discern
between various isoforms of the target protein, provides
the specificity needed for clinical analyses, while the use of
standard curve and an internal reference standard facili-
tates simultaneous analyte quantitation.
Our MSIA analysis of MIF has revealed unique qualita-
tive and quantitative profiles of MIF within individual
serum samples. Importantly, our work has facilitated the
discovery of variants of MIF that cannot be individually
discerned using conventional non-MS based immuno-
assay approaches. With the MSIA assay, we detected sev-
eral isoforms of MIF to be present endogenously within
serum samples, including cysteinylated and glycated MIF.
To our knowledge, these forms of MIF have not previ-
ously been detected or quantified from biological samples.
Of clinical relevance to metabolic disorders is protein
glycation, a non-enzymatic binding of glucose to pro-
teins [65]. Recent studies involving in vitro glycation and
subsequent in-solution proteolysis have enabled the elu-
cidation of glycation sites of recombinant proteins, in-
cluding HSA [66]. Given that glycation of MIF has not,
to our knowledge, been described previously, we pur-
sued further characterization of this modification, and
determined that MIF glycation can occur at any of the
three lysine residues.Differences in measured concentrations between sample
collection types, as we have observed for MIF, may be a
result of multiple factors. Various anticoagulants differ in
mechanisms [64], and certain additives may form com-
plexes with serum/plasma proteins, decreasing immuno-
reactivity [67]. Such differences have been reported in
various studies [67,68], Notably, Skogstrand et al. [69], in
a study of inflammatory markers, concluded that higher
measurable concentrations in serum compared to plasma
is due to the longer storage time for serum prior to centri-
fugation which allows, during the coagulation process, for
the gradual release of inflammatory markers that had been
sequestered by blood proteins they are associated with.
While discrepancies in quantitative measurements between
different sample collection types are somewhat unsurpris-
ing, our results suggest that quantitative comparisons be-
tween sample cohorts should only be made amongst
specimens of the same collection type.
A small negative bias of −17.7% was observed between
the MSIA and ELISA MIF analyses. The reason for the
bias is not clear, but interference from non-specific in-
teractions with the antibodies employed in the ELISA
analysis could play a role, resulting in elevated ELISA
measured concentrations of MIF compared to MSIA.
Biomarker assays have a long history in clinical use for
determining prognoses, assessment of response to therapy,
and in diagnostics [44,59], and recent years have seen the
emergence of diverse MS based quantitative assay method-
ologies. When developing a new quantitative method for
biomarker analysis, assay validation is critical to ensuring a
robust and reproducible method. However the criteria
used to validate assays can differ, and streamlining of valid-
ation criteria is needed to ensure reliable and reproducible
results. CLIA has put forth requirements for clinical labs
[70], and as proteomics research has brought about novel
techniques for quantitative protein analysis, interest has re-
cently emerged in the research community with regard to
harmonizing criteria for assay performance parameters.
This can help enable technology transfer. Though method-
ologies can vary greatly, Lee et al. [59] have suggested a
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range of analytical platforms; a set of recommended valid-
ation parameters that can be tailored to the specific needs
and intended utility of the study.
In the development of our MIF quantitative MSIA
assay, we have employed several of these validation mea-
sures, including intra- and inter-day precision, recovery,
and dilution linearity. In addition, we have also per-
formed assessment of protein stability, comparison with
another existing assay, and comparison of different
blood collection tubes. The inter-assay and intra-assay
CVs and the assay linearity and spiking recovery experi-
ments confirm the performance of the MIF MSIA assay.
In combining selective immunoaffinity enrichment of
protein analytes with mass spectrometry, detailed mo-
lecular analysis is enabled, with the ability to both iden-
tify and quantify different proteoforms. With this added
dimension of molecular heterogeneity, the MSIA assay
provides the unique capability to address the molecular
differences that may be present in diseased individuals
relative to healthy subjects. Post translational modifica-
tions (PTMs) of a protein may impart unique physiological
activities, and may be present in different proportions rela-
tive to the intact protein in the case of disease states. Ac-
cordingly, a targeted assay that examines the diversity of
proteoforms in sample populations can facilitate the iden-
tification of unique disease biomarkers based on protein
PTMs, potentially enabling more sensitive and specific de-
tection of disease.
The molecular heterogeneity that we have identified is
particularly interesting in light of the complex, multifa-
ceted nature of this protein. A cross sectional MSIA
study consisting of diverse diseased and non-disease pa-
tient samples may help elucidate the relationship between
the abundance of intact, cysteinylated, and glycated MIF
and the pathologies in which MIF may potentially play a
role. As such, our assay may be valuable for researchers




Anti-human MIF antibody was obtained from AbD
Serotec (Raleigh, NC). Recombinant Human MIF protein
was obtained from Fitzgerald (Acton, MA). Recombinant
C-terminal His tag MIF was purchased from Cell Sciences
(Canton, MA). N-methyl pyrrolidone (NMP) was obtained
from Fisher Scientific (Waltham, MA). Phosphate buffered
saline (PBS) and MES were obtained from Thermo Scien-
tific (Waltham, MA). HBS-N buffer (0.1 M HEPES, 1.5 M
NaCl) was prepared with NaCl and HEPES from Sigma-
Aldrich (St. Louis, MO). CDI (carbonyldiimidazole), sina-
pic acid, ethanolamine, human serum albumin (HSA),
n-octyl glucopyranoside, tween-20, ammonium acetate,D-(+)-glucose, diethylenetriaminepentaacetic acid (DTPA),
sodium azide, toluene, tris(2-carboxyethyl)phosphine
(TCEP), acetonitrile, and trifluoroacetic acid were ob-
tained from Sigma-Aldrich (St. Louis, MO).
Preparation of anti-MIF MSIA affinity pipettes
MSIA affinity pipette tips with porous microcolumns
were obtained from Thermo Fisher Scientific (Tempe,
AZ). Using a Beckman Multimek Automated 96-channel
robot, the MSIA affinity pipette tips were CDI-activated,
as described in previous protocols [71]. To the activated
MSIA pipettes, anti-MIF antibody from AbD Serotec
was covalently immobilized. It was empirically deter-
mined that 2.5 μg of antibody diluted in MES to a vol-
ume of 30 μL per well provided the optimal trade-off
between antibody cost and assay performance. The
antibody-derivatized MSIA tips were stored at 4°C until
later use.
Preparation of standard curve and analytical samples
We developed a 6-point standard curve to enable MIF
quantification in biological samples. Prior to analysis,
samples were thawed on ice, and centrifuged at 12,700 g
for 5 minutes. A standard curve was performed in paral-
lel with each sample run. For the assay standards, we
used recombinant MIF protein from Fitzgerald. To per-
form the standard curve, the MIF recombinant protein
was serially diluted in a solution of 10 mg/mL HSA in
PBS. The concentrations of the MIF standards ranged
from 1.56 to 50 ng/mL. His tag MIF, prepared at a con-
centration of 20 ng/mL in 10 ng/mL HSA in PBS, was
used as an internal reference standard for quantitative
analysis. A 200 μL aliquot of 20 ng/mL His tag MIF was
added to 200 μL of samples and standards. The samples
tray was then incubated at room temperature on a plate
shaker at 750 RPM for 2 minutes to mix the sample and
internal standard. A 100 μL aliquot of detergent buffer
(1.5 M ammonium acetate, 0.15 M N-octyl-glucopyrano-
side, concentrated PBS (0.67 mol/L sodium phosphate,
1 M NaCl), and 4.4% v/v tween-20) was added to all
samples and standards immediately prior to MSIA
extraction.
Mass spectrometric immunoassay
Following preparation of standards and samples, immuno-
affinity extraction of MIF was carried out on a Beckman
Multimek 96-channel robotic workstation, with MSIA
affinity pipettes derivatized with AbD Serotec anti-MIF
antibody. The pipettes were first pre-rinsed via 10 aspir-
ation and dispense cycles in a volume of 150 μL PBS
w/0.1% Tween. Next, 1000 aspiration and dispense cy-
cles in the samples (500 μL total sample volume) were
performed to allow for the flow of sample through the
microcolumns and enable extraction of MIF from the
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tially with PBS w/0.1% tween (75 aspiration and dis-
pense cycles, 150 μL volume), H2O (20 cycles, 150 μL),
100 mM TrisHCl (10 cycles, 150 μL) and H2O (30 cycles,
150 μL). Elution of captured protein onto the MALDI
target was achieved via aspiration of 6 μL of sinapic acid
matrix (a saturated aqueous solution containing 33% v/v
acetonitrile and 0.4% v/v trifluoroacetic acid) followed
by 28 aspirate and dispense cycles and subsequent re-
lease of the droplets onto the MALDI target. The drop-
lets were air-dried to allow for co-crystallization of the
matrix and proteins. Mass spectra were acquired on a
Bruker Ultraflex MALDI-TOF mass spectrometer oper-
ating in positive-ion, delayed extraction linear mode,
with ion source 1 at 25.00 kV, ion source 2 at 23.10 kV,
lens at 9.00 kV, 90 ns delay, and 1 GS/s sample rate. Ap-
proximately 5,000 laser shots were acquired for each
mass spectrum and summed. Prior to acquisition of the
mass spectra, the target mass range was externally cali-
brated using a mixture of calibrants obtained from
Bruker Daltonics (Billerica, MA), consisting of insulin,
ubiquitin, cytochrome C and myoglobin. The calibrant
mix was diluted 15-fold in sinapic acid matrix and
1 μL spotted onto the MALDI target. Following data
collection, the mass spectra was imported into Bruker
Daltonics FlexAnalysis software, smoothed (Savitzky-Golay
algorithm) and baseline subtracted (Tophat algorithm).
All MIF peak intensities are entered into an Excel spread-
sheet. The ratio of peak intensities of MIF standards to
His tag MIF was plotted against the concentrations of the
MIF standards to create the standard curve. The concen-
trations of endogenous human MIF, including intact,
cysteinylated and glycated MIF, were computed using the
equation from the standard curve.
Human samples
Healthy pooled human plasma for initial assay develop-
ment was purchased from PromedDx (Norton, MA).
Healthy male serum samples were purchased from Pro-
medDx (Norton, MA). The samples were de-identified
and labeled with only a barcode. We utilized 22 of these
samples, which ranged in age from 46 to 73 for analysis
by MSIA and ELISA assays. Matched sets, consisting of
5 sample collection types for each individual were ob-
tained from Bioreclamation (Hicksville, NY). The sam-
ples were de-identified and labeled with only a barcode.
Sample types included: 3.8% NaCitrate plasma, K2EDTA
plasma, K3EDTA plasma, Na2EDTA plasma, and serum.
We analyzed 5 sample collection types from 6 individ-
uals (30 samples total).
In vitro glycation of MIF
To perform in vitro glycation, 1 mg/mL recombinant
MIF protein was incubated with 0.5 M glucose solutionin a 1:1 volume ratio. The glucose solution contained
0.2 M sodium phosphate buffer with 1 mM diethylene-
triaminepentaacetic acid (DTPA) added to chelate trace
amounts of transition metal ions (e.g. iron, copper, etc.)
from the phosphate buffer which may otherwise catalyze
unintended auto-oxidation reactions [72]. A 5% w/v so-
dium azide was added to the glucose-MIF solution to in-
hibit bacterial growth. A drop of toluene was added to the
surface with a pasteur pipet to prevent sample evapor-
ation. The solution was incubated at 37°C. After 11 days, a
mixture of 40% unmodified, 42% singly glycated, and 18%
doubly glycated MIF was obtained.
In solution pepsin digest
To perform in-solution pepsin digest, 12 μL of 10 mM
HCl, 2 μL of 50 mM TCEP in water, 1 μL of acetonitrile,
and 1 μL of 0.2 g/L porcine pepsin were added to 10 μL
recombinant MIF. Ten minutes after addition of pepsin
solution (incubation at room temperature), 1 μL of the
digest was diluted 5× with alpha cyano 4-hydroxy cinna-
minic acid matrix solution (a saturated aqueous matrix so-
lution with 33% v/v acetonitrile and 0.4% v/v trifluoroacetic
acid) and all 5 μL were spotted on the target. The matrix-
analyte droplet was air-dried. Mass spectra were acquired
on a Bruker Ultraflex operating in positive-ion reflectron
mode, with ion source 1 at 25.00 kV, ion source 2 at
21.90 kV, lens at 9.50 kV, 190 ns delay, and 2 GS/s sample
rate. Approximately 1000 laser shots were acquired and
summed for each mass spectrum. Prior to data acquisi-
tion, the target mass range was externally calibrated with
a mixture of peptide calibrants obtained from Bruker
Daltonics (Billerica, MA) consisting of bradykinin, angio-
tensin II, angiotensin I, Substance P, bombesin, ACTH
(1–17), ACTH (18–39), and somatostatin. After data ac-
quisition, the mass spectra were imported into MoverZ
software. Peptides corresponding to C-terminal cleavages
at Phe, Leu, Tyr, and Trp, with up to 10 missed cleavages,
were identified and the mass list was exported into PAWS
software (Proteometrics, LLC).
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